UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/15.01.25 | Real-time BOERSE MUENCHEN 08:41:12 06/06/2024 BST | ||
| 2.31 EUR | 0.00% |
|
| Current month | +60.42% | ||
| 1 month | +272.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 06/06/24 | 2.31 | 0.00% |
| 05/06/24 | 2.31 | +17.26% |
| 04/06/24 | 1.97 | +15.88% |
| 03/06/24 | 1.7 | +18.06% |
| 31/05/24 | 1.44 | +21.01% |
Real-time BOERSE MUENCHEN
Last update June 06, 2024 at 08:41 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC620S |
| ISIN | DE000HC620S7 |
| Date issued | 14/04/2023 |
| Strike | 550 $ |
| Maturity | 15/01/2025 (224 Days) |
| Parity | 10 : 1 |
| Emission price | 1.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.75 € |
|---|---|
| Lowest since issue | 0.53 € |
| Spread | 0.14 € |
| Spread % | 6.01% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant
